WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports …
KAIT1mon
In a report published Tuesday, Piper Jaffray analyst Joshua Schimmer maintained an Overweight rating on Vanda Pharmaceuticals (NASDAQ: VNDA) and maintained a price target of $21.00. In the report, Piper Jaffray says "We are …
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports …
WAFB1mon
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports …
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports …
WTVM1mon
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports …
WSFA1mon
MYL closed Thursday's trading at $42.85, down 0.70%. Shares of Vanda Pharmaceuticals Inc. (VNDA) soared more than 20% on Thursday, following a favorable verdict in the patent litigation against Roxane Laboratories Inc. related to …
Vanda Pharmaceuticals Inc : Vanda pharmaceuticals reports second quarter 2016 financial results . Vanda reiterates 2016 net product sales guidance of $143 million to $153 million . Qtrly loss per share $0.11; revenue $36.03 million . Says …
Drug maker Vanda Pharmaceuticals (NASDAQ:VNDA) has reached an exclusive license agreement with Israel-based biotech firm Megapharm to sell its schizophrenia medicine Fanapt, the company reported Tuesday. Under the deals …
Among large-cap pharma stocks, Bayer (BAYRY), a Zacks Rank #2 (Buy) stock, looks well-positioned with several new products -- Eylea, Stivarga and Xarelto -- in its portfolio. These products represent significant commercial potential. We …